Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia

Seth E. Karol, Wenjian Yang, Sara L. Van Driest, Tamara Y. Chang, Sue Kaste, Erica Bowton, Melissa Basford, Lisa Bastarache, Dan M. Roden, Joshua C. Denny, Eric Larsen, Naomi Winick, William L. Carroll, Cheng Cheng, Deqing Pei, Christian A. Fernandez, Chengcheng Liu, Colton Smith, Mignon L. Loh, Elizabeth A. Raetz & 8 others Stephen P. Hunger, Paul Scheet, Sima Jeha, Ching Hon Pui, William E. Evans, Meenakshi Devidas, Leonard A. Mattano, Mary V. Relling

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors for osteonecrosis. We performed a genome-wide association study of single nucleotide polymorphisms (SNPs) in a discovery cohort comprising 2285 children with ALL, treated on the Children's Oncology Group AALL0232 protocol (NCT00075725), adjusting for covariates. The minor allele at SNP rs10989692 (near the glutamate receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio 5 2.03; P 5 3.59 3 1027). The association was supported by 2 replication cohorts, including 361 children with ALL on St. Jude's Total XV protocol (NCT00137111) and 309 non-ALL patients from Vanderbilt University's BioVU repository treated with glucocorticoids (odds ratio [OR]51.87 and 2.26;P5.063 and .0074, respectively). In ameta-analysis, rs10989692 was also highest ranked (P 5 2.68 3 1028), and the glutamate pathway was the top ranked pathway (P 5 9.8 3 1024). Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia (OR 5 1.64; P 5 2.5 3 1023), and arterialembolismandthrombosis (OR51.88;P54.231023). In conclusion,osteonecrosiswas associatedwith inheritedvariations near glutamate receptor genes. Further understandingthis associationmay allow interventions to decrease osteonecrosis. These trials are registered at www.clinicaltrials.gov as #NCT00075725 and #NCT00137111.

Original languageEnglish (US)
Pages (from-to)1770-1776
Number of pages7
JournalBlood
Volume126
Issue number15
DOIs
StatePublished - 2015

Fingerprint

Osteonecrosis
Glutamate Receptors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glucocorticoids
Polymorphism
Nucleotides
Genes
Oncology
Single Nucleotide Polymorphism
Odds Ratio
Glutamic Acid
Hazards
Genome-Wide Association Study
Brain Ischemia
Blood Vessels
Alleles
Genetics
Phenotype

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Medicine(all)
  • Hematology
  • Cell Biology

Cite this

Karol, S. E., Yang, W., Van Driest, S. L., Chang, T. Y., Kaste, S., Bowton, E., ... Relling, M. V. (2015). Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 126(15), 1770-1776. https://doi.org/10.1182/blood-2015-05-643601

Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. / Karol, Seth E.; Yang, Wenjian; Van Driest, Sara L.; Chang, Tamara Y.; Kaste, Sue; Bowton, Erica; Basford, Melissa; Bastarache, Lisa; Roden, Dan M.; Denny, Joshua C.; Larsen, Eric; Winick, Naomi; Carroll, William L.; Cheng, Cheng; Pei, Deqing; Fernandez, Christian A.; Liu, Chengcheng; Smith, Colton; Loh, Mignon L.; Raetz, Elizabeth A.; Hunger, Stephen P.; Scheet, Paul; Jeha, Sima; Pui, Ching Hon; Evans, William E.; Devidas, Meenakshi; Mattano, Leonard A.; Relling, Mary V.

In: Blood, Vol. 126, No. 15, 2015, p. 1770-1776.

Research output: Contribution to journalArticle

Karol, SE, Yang, W, Van Driest, SL, Chang, TY, Kaste, S, Bowton, E, Basford, M, Bastarache, L, Roden, DM, Denny, JC, Larsen, E, Winick, N, Carroll, WL, Cheng, C, Pei, D, Fernandez, CA, Liu, C, Smith, C, Loh, ML, Raetz, EA, Hunger, SP, Scheet, P, Jeha, S, Pui, CH, Evans, WE, Devidas, M, Mattano, LA & Relling, MV 2015, 'Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia', Blood, vol. 126, no. 15, pp. 1770-1776. https://doi.org/10.1182/blood-2015-05-643601
Karol, Seth E. ; Yang, Wenjian ; Van Driest, Sara L. ; Chang, Tamara Y. ; Kaste, Sue ; Bowton, Erica ; Basford, Melissa ; Bastarache, Lisa ; Roden, Dan M. ; Denny, Joshua C. ; Larsen, Eric ; Winick, Naomi ; Carroll, William L. ; Cheng, Cheng ; Pei, Deqing ; Fernandez, Christian A. ; Liu, Chengcheng ; Smith, Colton ; Loh, Mignon L. ; Raetz, Elizabeth A. ; Hunger, Stephen P. ; Scheet, Paul ; Jeha, Sima ; Pui, Ching Hon ; Evans, William E. ; Devidas, Meenakshi ; Mattano, Leonard A. ; Relling, Mary V. / Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. In: Blood. 2015 ; Vol. 126, No. 15. pp. 1770-1776.
@article{021e58812f6346bf800366f59317870c,
title = "Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia",
abstract = "Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors for osteonecrosis. We performed a genome-wide association study of single nucleotide polymorphisms (SNPs) in a discovery cohort comprising 2285 children with ALL, treated on the Children's Oncology Group AALL0232 protocol (NCT00075725), adjusting for covariates. The minor allele at SNP rs10989692 (near the glutamate receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio 5 2.03; P 5 3.59 3 1027). The association was supported by 2 replication cohorts, including 361 children with ALL on St. Jude's Total XV protocol (NCT00137111) and 309 non-ALL patients from Vanderbilt University's BioVU repository treated with glucocorticoids (odds ratio [OR]51.87 and 2.26;P5.063 and .0074, respectively). In ameta-analysis, rs10989692 was also highest ranked (P 5 2.68 3 1028), and the glutamate pathway was the top ranked pathway (P 5 9.8 3 1024). Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia (OR 5 1.64; P 5 2.5 3 1023), and arterialembolismandthrombosis (OR51.88;P54.231023). In conclusion,osteonecrosiswas associatedwith inheritedvariations near glutamate receptor genes. Further understandingthis associationmay allow interventions to decrease osteonecrosis. These trials are registered at www.clinicaltrials.gov as #NCT00075725 and #NCT00137111.",
author = "Karol, {Seth E.} and Wenjian Yang and {Van Driest}, {Sara L.} and Chang, {Tamara Y.} and Sue Kaste and Erica Bowton and Melissa Basford and Lisa Bastarache and Roden, {Dan M.} and Denny, {Joshua C.} and Eric Larsen and Naomi Winick and Carroll, {William L.} and Cheng Cheng and Deqing Pei and Fernandez, {Christian A.} and Chengcheng Liu and Colton Smith and Loh, {Mignon L.} and Raetz, {Elizabeth A.} and Hunger, {Stephen P.} and Paul Scheet and Sima Jeha and Pui, {Ching Hon} and Evans, {William E.} and Meenakshi Devidas and Mattano, {Leonard A.} and Relling, {Mary V.}",
year = "2015",
doi = "10.1182/blood-2015-05-643601",
language = "English (US)",
volume = "126",
pages = "1770--1776",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia

AU - Karol, Seth E.

AU - Yang, Wenjian

AU - Van Driest, Sara L.

AU - Chang, Tamara Y.

AU - Kaste, Sue

AU - Bowton, Erica

AU - Basford, Melissa

AU - Bastarache, Lisa

AU - Roden, Dan M.

AU - Denny, Joshua C.

AU - Larsen, Eric

AU - Winick, Naomi

AU - Carroll, William L.

AU - Cheng, Cheng

AU - Pei, Deqing

AU - Fernandez, Christian A.

AU - Liu, Chengcheng

AU - Smith, Colton

AU - Loh, Mignon L.

AU - Raetz, Elizabeth A.

AU - Hunger, Stephen P.

AU - Scheet, Paul

AU - Jeha, Sima

AU - Pui, Ching Hon

AU - Evans, William E.

AU - Devidas, Meenakshi

AU - Mattano, Leonard A.

AU - Relling, Mary V.

PY - 2015

Y1 - 2015

N2 - Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors for osteonecrosis. We performed a genome-wide association study of single nucleotide polymorphisms (SNPs) in a discovery cohort comprising 2285 children with ALL, treated on the Children's Oncology Group AALL0232 protocol (NCT00075725), adjusting for covariates. The minor allele at SNP rs10989692 (near the glutamate receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio 5 2.03; P 5 3.59 3 1027). The association was supported by 2 replication cohorts, including 361 children with ALL on St. Jude's Total XV protocol (NCT00137111) and 309 non-ALL patients from Vanderbilt University's BioVU repository treated with glucocorticoids (odds ratio [OR]51.87 and 2.26;P5.063 and .0074, respectively). In ameta-analysis, rs10989692 was also highest ranked (P 5 2.68 3 1028), and the glutamate pathway was the top ranked pathway (P 5 9.8 3 1024). Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia (OR 5 1.64; P 5 2.5 3 1023), and arterialembolismandthrombosis (OR51.88;P54.231023). In conclusion,osteonecrosiswas associatedwith inheritedvariations near glutamate receptor genes. Further understandingthis associationmay allow interventions to decrease osteonecrosis. These trials are registered at www.clinicaltrials.gov as #NCT00075725 and #NCT00137111.

AB - Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors for osteonecrosis. We performed a genome-wide association study of single nucleotide polymorphisms (SNPs) in a discovery cohort comprising 2285 children with ALL, treated on the Children's Oncology Group AALL0232 protocol (NCT00075725), adjusting for covariates. The minor allele at SNP rs10989692 (near the glutamate receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio 5 2.03; P 5 3.59 3 1027). The association was supported by 2 replication cohorts, including 361 children with ALL on St. Jude's Total XV protocol (NCT00137111) and 309 non-ALL patients from Vanderbilt University's BioVU repository treated with glucocorticoids (odds ratio [OR]51.87 and 2.26;P5.063 and .0074, respectively). In ameta-analysis, rs10989692 was also highest ranked (P 5 2.68 3 1028), and the glutamate pathway was the top ranked pathway (P 5 9.8 3 1024). Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia (OR 5 1.64; P 5 2.5 3 1023), and arterialembolismandthrombosis (OR51.88;P54.231023). In conclusion,osteonecrosiswas associatedwith inheritedvariations near glutamate receptor genes. Further understandingthis associationmay allow interventions to decrease osteonecrosis. These trials are registered at www.clinicaltrials.gov as #NCT00075725 and #NCT00137111.

UR - http://www.scopus.com/inward/record.url?scp=84984608981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984608981&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-05-643601

DO - 10.1182/blood-2015-05-643601

M3 - Article

VL - 126

SP - 1770

EP - 1776

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -